Sandoz Group (OTCMKTS:SDZNY) Upgraded at The Goldman Sachs Group

Key Points

• Goldman Sachs upgraded Sandoz Group (OTCMKTS:SDZNY) to a "strong-buy" rating in a note to investors on Wednesday.
• Analyst coverage is mixed—two firms rate the stock Strong Buy and two rate it Hold—leaving a MarketBeat consensus rating of "Buy".
• SDZNY opened at $80.29, trades near its 50‑day moving average ($81.58) above its 200‑day ($72.60), and has a 52‑week range of $35.61–$94.15, indicating significant price volatility.

Sandoz Group (OTCMKTS:SDZNY - Get Free Report) was upgraded by research analysts at The Goldman Sachs Group to a "strong-buy" rating in a note issued to investors on Wednesday,Zacks.com reports.

SDZNY has been the topic of a number of other research reports. Barclays lowered shares of Sandoz Group from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 26th. Royal Bank Of Canada downgraded shares of Sandoz Group from a "moderate buy" rating to a "hold" rating in a research note on Monday, March 23rd. Finally, Jefferies Financial Group upgraded shares of Sandoz Group from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 12th. Two research analysts have rated the stock with a Strong Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy".

Sandoz Group Price Performance

SDZNY opened at $80.29 on Wednesday. The stock's 50 day moving average price is $81.58 and its 200-day moving average price is $72.60. Sandoz Group has a 52-week low of $35.61 and a 52-week high of $94.15.

Sandoz Group Company Profile

Sandoz Group OTCMKTS: SDZNY is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company's product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.